Tylenol Autism & ADHD Lawsuit Attorneys

Tylenol Autism & ADHD Lawsuit Attorneys

Acetaminophen, the main ingredient in Tylenol and other over-the-counter medications, may be linked to birth defects and developmental disorders when taken during pregnancy. People whose children may have been harmed by pregnancy-related acetaminophen use may be eligible for compensation.

Open, accepting new clients
Free Consultation - No Obligation

Complete this form to have our firm review your case for free.

All required fields are marked with an asterisk "*"
Name(Required)
State(Required)

By submitting this form I agree to the terms of SeegerWeiss.com Terms & Conditions and Privacy Policy.

This field is for validation purposes and should be left unchanged.

Our Role

Seeger Weiss represents plaintiffs against Tylenol manufacturer Johnson & Johnson for medical birth defects including autism spectrum disorder, ADHD, and reproductive disorders caused after women took Tylenol or other acetaminophen medications while pregnant.

Case Updates

  • 9/22/23

    The plaintiffs put forth their five general causation experts: Dr. Andrea Baccarelli, Dr. Robert Cabrera, Dr. Eric Hollander, Dr. Stan G. Louie, and Dr. Brandon Pearson. The plaintiffs also moved to exclude defendants’ experts.

  • 9/19/23

    Initial Daubert motions were filed arguing against the admissibility of the scientific expert evidence being presented. A Daubert hearing is expected in October 2023.

  • 9/18/23

    As of September 18, 2023, 265 lawsuits have been filed in In Re: Acetaminophen – ASD/ADHD Products Liability Litigation.

  • 7/28/23

    Judge Cote granted the government’s request to file a Statement of Interest regarding plaintiff’s proposal to include a warning on Tylenol bottles that references the risk of Autism and ADHD with frequent use during pregnancy by September 15, 2023.

  • 6/15/23

    As of June 15, 2023, 136 lawsuits have been filed in In Re: Acetaminophen – ASD/ADHD Products Liability Litigation.

  • 4/20/23

    Judge Cote denied Johnson & Johnson’s motion to dismiss based on the federal preemption doctrine. In her ruling, the judge stated that FDA regulations did not prohibit Johnson & Johnson from adding a warning to Tylenol containers about the risks of taking Tylenol while pregnant.

  • 4/19/23

    Judge Cote requested the government’s opinion on plaintiff’s proposal to include a warning on Tylenol bottles that references the risk of Autism and ADHD with frequent use during pregnancy. The proposal is currently under advisement by the FDA.

  • 2/22/23

    Judge Cote issued an Order finalizing the protocol, rules and schedule for depositions and fact discovery of expert witnesses. Those depositions can now begin and will play a key role in an October 2023 hearing, when Judge Conte plans to rule the plaintiffs’ causation evidence.

  • 2/16/23

    As of February 16, 2022, 107 lawsuits have been filed in In Re: Acetaminophen – ASD/ADHD Products Liability Litigation.

  • 1/9/22

    The court approved a Short Form Complaint for new incoming plaintiffs to use when filing acetaminophen autism and ADHD lawsuits.

  • 11/15/22

    Judge Denise Cote denied Walmart’s motion to dismiss and explained that federal preemption does not apply. Judge Cote stated that the FDA regulation does not prohibit Walmart from changing the warning labels on its generic Tylenol products. She noted that the applicable federal labeling laws are not “exclusive” and do not limit a manufacturer’s obligation to ensure that its label is adequate.

  • 11/13/22

    Walmart filed a motion to dismiss the Tylenol autism cases based on federal preemption. The company argued that the FDA mandated the warning labels on these products under federal law; therefore, Walmart was not permitted to change the labels.

  • 10/5/22

    The Judicial Panel on Multidistrict Litigation consolidated 18 lawsuits alleging prenatal exposure to acetaminophen caused children to developed autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), or both for pretrial proceedings before U.S. District Judge Denise Cote in the Southern District of New York. The panel sent an additional 48 cases to the newly created multidistrict litigation the following day, saying the same scientific and legal questions underlie all of the cases.